Abstract:Capsid assembly modulators (CAMs) have recently been revealed to be effective in blocking HBV replication. HBV capsid protein inhibitors reduce and ultimately eliminate HBV by inhibiting virus replication and blocking hepatocyte infection. Sulfonamides are synthetic functional groups in development of different kinds of drugs. Sulfonyl benzamide clinical drugs NVR 3-778 and BA-38017 are lead compounds in discovery of antiviral compounds with increased activity and reduced cytotoxicity by drug design strategies including pharmacophore hybrid, bioisosterism and scaffold hopping. In current study, three series of target compounds were synthesized, and their anti-HBV activity was evaluated against HepAD38 cells. Compound 5a (EC<sub>50</sub> = 0.50 ± 0.07 μM, CC<sub>50</sub> = 48.16 ± 9.15 μM) showed better anti-HBV DNA replication activity than the lead compound BA-38017, and showed good inhibitory effect on the assembly of HBV capsid protein compared with the clinical drug NVR 3-778. In addition, preliminary structure-activity relationship (SAR) and molecular docking studies were conducted to explore potential interactions and binding modes between compounds and target proteins, which may help researchers to find more effective anti-HBV drugs.

Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents.

Design, Synthesis, Molecular Docking Studies and Anti-Hbv Activity of Phenylpropanoid Derivatives

Synthesis and Biological Evaluation of Phenylpropanoid Derivatives

Discovery of 5-Alkyl-2-pyrazol-oxazolidin-4-one Derivatives As Novel Hepatitis B Virus Capsid Assembly Modulators

Design, synthesis, and antihepatitis B virus activities of novel 2-pyridone derivatives.

Design and Synthesis of (3-Phenylisoxazol-5-yl)methanimine Derivatives as Hepatitis B Virus Inhibitors

Design, Synthesis, And Bioactive Screen In Vitro Of Cyclohexyl (E)-4-(Hydroxyimino)-4-Phenylbutanoates And Their Ethers For Anti-Hepatitis B Virus Agents

Design, Synthesis and Primary Biological Evaluation of the Novel 2-Pyridone Derivatives As Potent Non-Nucleoside HBV Inhibitors.

Design and Synthesis of Novel Benzimidazole Derivatives As Inhibitors of Hepatitis B Virus

Synthesis and Evaluation of 3-Phenylisoxazoline Derivatives As Non-Nucleoside Hepatitis B Virus Inhibitors

Discovery and Biological Evaluation of 2-((3-phenylisoxazol-5-yl) Methoxy) Benzamide Derivatives As Potent Nucleocapsid Inhibitors

Synthesis and anti-hepatitis B virus activity of a novel class of thiazolylbenzimidazole derivatives.

Design, synthesis and biological evaluation of novel dihydrobenzodioxine derivatives as HBV capsid protein inhibitors

Design, Diversity-Oriented Synthesis and Biological Evaluation of Novel Heterocycle Derivatives As Non-Nucleoside HBV Capsid Protein Inhibitors.

Discovery and optimizing polycyclic pyridone compounds as anti-HBV agents

Design, Synthesis and Bioactive Evaluation of Oxime Derivatives of Dehydrocholic Acid as Anti-Hepatitis B Virus Agents

Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion.

Synthesis and Anti-Hepatitis B Virus Activity of Novel Benzimidazole Derivatives

Study on 2-arylthio-5-iodo pyrimidine derivatives as novel nonnucleoside inhibitors against hepatitis B virus DNA replication.

Discovery Of Oxime Ethers As Hepatitis B Virus (Hbv) Inhibitors By Docking, Screening And In Vitro Investigation

Design, Synthesis and Evaluation of Pyrazole Derivatives As Non-Nucleoside Hepatitis B Virus Inhibitors